Tapewire

OTC · USD

SMNR

Semnur Pharmaceuticals, Inc.

Export transactions ↓
Tapewire entity
6623
SEC CIK
0001913577
Parsed reports
23

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 15, 2026 Filed Jun 26, 2026 20:19 UTC
Scilex, Inc.10% owner
OtherCommon Stock 7,034,737 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-285524 · ownership.xml · nonDerivative · entry 1

Scilex Holding Co · CIK 0001820190 · 10% owner

Scilex, Inc. · CIK 0002084647 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Scilex, Inc.

Disclosed balance after: 174,770,112

F1 · kind: On June 15, 2026, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares of common stock of Semnur Pharmaceuticals, Inc. ("Semnur") held by the Reporting Person (the "Dividend Shares") to record holders of (i) the Reporting Person's common stock, (ii) certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible into shares of the Reporting Person's common stock as of June 1, 2026 (the "Record Date" and the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders").

F2 · kind: An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of the Additional Participating Holders who may be entitled to such shares pursuant to the terms of the applicable warrants and convertible notes following the exercise or conversion thereof, and at the time such shares are distributed to the applicable warrantholders and noteholders, the Reporting Person will file a Form 4 reporting such distribution.

F1 · shares: On June 15, 2026, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares of common stock of Semnur Pharmaceuticals, Inc. ("Semnur") held by the Reporting Person (the "Dividend Shares") to record holders of (i) the Reporting Person's common stock, (ii) certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible into shares of the Reporting Person's common stock as of June 1, 2026 (the "Record Date" and the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders").

F2 · shares: An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of the Additional Participating Holders who may be entitled to such shares pursuant to the terms of the applicable warrants and convertible notes following the exercise or conversion thereof, and at the time such shares are distributed to the applicable warrantholders and noteholders, the Reporting Person will file a Form 4 reporting such distribution.

Read SEC document
September 23, 2025 Filed Sep 25, 2025 23:49 UTC
Scilex, Inc.10% owner
SaleCommon Stock 554,849 $16.00 $8,877,584.00
Disclosure

SEC source: 0001193125-25-218151 · ownership.xml · nonDerivative · entry 2

Scilex Holding Co · CIK 0001820190 · 10% owner

Scilex, Inc. · CIK 0002084647 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

F1 · kind: The transactions reported on this Form 4 were effected pursuant to that certain Securities Purchase Agreement, dated September 23, 2025, by and among the Reporting Persons, the Issuer, and Biconomy PTE.LTD, as buyer.

F2 · price: The purchase price was paid in Bitcoin blockchain based on the spot exchange rate for Bitcoin as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the closing date of the purchase.

Read SEC document
September 23, 2025 Filed Sep 25, 2025 23:49 UTC
Scilex, Inc.10% owner
SaleCommon Stock 11,945,151 $16.00 $191,122,416.00
Disclosure

SEC source: 0001193125-25-218151 · ownership.xml · nonDerivative · entry 1

Scilex Holding Co · CIK 0001820190 · 10% owner

Scilex, Inc. · CIK 0002084647 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Scilex, Inc.

Disclosed balance after: 181,804,849

F1 · kind: The transactions reported on this Form 4 were effected pursuant to that certain Securities Purchase Agreement, dated September 23, 2025, by and among the Reporting Persons, the Issuer, and Biconomy PTE.LTD, as buyer.

F2 · price: The purchase price was paid in Bitcoin blockchain based on the spot exchange rate for Bitcoin as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the closing date of the purchase.

Read SEC document
August 30, 2024 Filed Sep 16, 2024 10:05 UTC SaleClass B Ordinary Shares · Derivative 500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-24-078775 · ownership.xml · derivative · entry 1

Denali Capital Global Investments LLC · CIK 0001920832 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,432,500

Underlying: Class B Ordinary Shares · 500,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

F2 · kind: On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company ("Scilex") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the "SIPA"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the "Cash Consideration") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the "Scilex Shares"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger.

F2 · price: On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company ("Scilex") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the "SIPA"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the "Cash Consideration") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the "Scilex Shares"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger.

F1 · derivative.exercise_date: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

F1 · derivative.expiration_date: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

Read SEC document
August 30, 2024 Filed Sep 16, 2024 14:01 UTC
Xu Jiandong10% owner
SaleClass B Ordinary Shares · Derivative 500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-24-078774 · ownership.xml · derivative · entry 1

Xu Jiandong · CIK 0001920399 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,432,500

Underlying: Class B Ordinary Shares · 500,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

F2 · kind: On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company ("Scilex") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the "SIPA"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the "Cash Consideration") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the "Scilex Shares"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger.

F2 · price: On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company ("Scilex") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the "SIPA"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the "Cash Consideration") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the "Scilex Shares"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger.

F1 · derivative.exercise_date: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

F1 · derivative.expiration_date: The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

F3 · ownership.direct: These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F3 · ownership.nature: These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document
May 21, 2022 Filed May 24, 2022 16:18 UTC Disposition to issuerClass B Ordinary Shares · Derivative 93,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-011621 · doc1.xml · derivative · entry 1

Denali Capital Global Investments LLC · CIK 0001920832 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,932,500

Underlying: Class A Ordinary Shares · 93,750 shares

Expires not disclosed

F1 · derivative.exercise_price: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

F2 · kind: As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by the Reporting Person, depending on the extent to which the underwriters' over-allotment option is exercised. The underwriters only partially exercised their over-allotment option, resulting in the Reporting Person forfeiting 93,750 Class B ordinary shares.

F2 · price: As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by the Reporting Person, depending on the extent to which the underwriters' over-allotment option is exercised. The underwriters only partially exercised their over-allotment option, resulting in the Reporting Person forfeiting 93,750 Class B ordinary shares.

F1 · derivative.exercise_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

F1 · derivative.expiration_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

Read SEC document
May 21, 2022 Filed May 24, 2022 20:20 UTC
Xu Jiandong10% owner
Disposition to issuerClass B Ordinary Shares · Derivative 93,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-011622 · doc1.xml · derivative · entry 1

Xu Jiandong · CIK 0001920399 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,932,500

Underlying: Class A Ordinary Shares · 93,750 shares

Expires not disclosed

F1 · derivative.exercise_price: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

F2 · kind: As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by Denali Capital Global Investments LLC (the "Sponsor"), depending on the extent to which the underwriters' over-allotment option is exercised. The underwriters only partially exercised their over-allotment option, resulting in the Sponsor forfeiting 93,750 Class B ordinary shares.

F2 · price: As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by Denali Capital Global Investments LLC (the "Sponsor"), depending on the extent to which the underwriters' over-allotment option is exercised. The underwriters only partially exercised their over-allotment option, resulting in the Sponsor forfeiting 93,750 Class B ordinary shares.

F1 · derivative.exercise_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

F1 · derivative.expiration_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date.

F3 · ownership.direct: These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F3 · ownership.nature: These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 16:54 UTC PurchaseClass A Ordinary Shares 510,000 $10.00 $5,100,000.00
Disclosure

SEC source: 0001140361-22-014407 · form4.xml · nonDerivative · entry 1

Denali Capital Global Investments LLC · CIK 0001920832 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 510,000

F1 · shares: Represents Class A Ordinary Shares underlying units (each unit having a price of $10.00 and consisting of one Class A Ordinary Share and one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A Ordinary Share at a price of $11.50 per share) that were acquired by the Reporting Person in a private placement effected concurrently with the closing of the Issuer's initial public offering, based on the partial exercise of the underwriters' over-allotment option.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 20:51 UTC
Xu Jiandong10% owner
PurchaseClass A Ordinary Shares 510,000 $10.00 $5,100,000.00
Disclosure

SEC source: 0001140361-22-014405 · form4.xml · nonDerivative · entry 1

Xu Jiandong · CIK 0001920399 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 510,000

F1 · shares: Represents Class A Ordinary Shares underlying units (each unit having a price of $10.00 and consisting of one Class A Ordinary Share and one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A Ordinary Share at a price of $11.50 per share) that were acquired by Denali Capital Global Investments LLC (the "Sponsor") in a private placement effected concurrently with the closing of the Issuer's initial public offering, based on the partial exercise of the underwriters' over-allotment option.

F2 · ownership.direct: These Class A Ordinary Shares underlying units are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares underlying units held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares underlying units held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F2 · ownership.nature: These Class A Ordinary Shares underlying units are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares underlying units held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares underlying units held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.